Dr. Desmond Adler joined Gentuity in early 2021 as President of Cardiovascular with the personal goal of enabling interventional cardiologists to improve how they care for their patients. Desmond sees the convergence of advanced imaging technology, artificial intelligence, and user-centric design as critical to achieving this goal and sees the Gentuity platform as uniquely positioned to deliver these innovations to the clinic. Desmond has over 20 years of experience in the biomedical optics industry and has contributed to new product launches in cardiology, ophthalmology, gastroenterology, and pulmonology. During his time at LightLab Imaging and St. Jude Medical, Desmond led the development of previous generations of intravascular imaging systems. He also led the development and commercialization of drug-device combination therapies for rare ophthalmic diseases as General Manager and VP R&D of Corneal Health for Glaukos Corp.

Desmond feels that working in medical technology represents a unique way to contribute to society while also experiencing lifelong learning, enjoying professional growth, and forming personal bonds with exceptional individuals from all over the world. Desmond holds a BSc in electrical engineering from the University of Alberta and a PhD in electrical engineering and computer science from MIT.

Charles Allan is passionate about using really small things to solve big problems. Being surrounded by many successful and supportive entrepreneurs, he quickly gained the ability to create teams and transform problems into solutions.

An example of his passion at work can be found during his undergraduate years at Queens University, where he helped build a microfluidic pump for an implantable therapeutic for glaucoma. This project helped ignite his entrepreneurial spirit, and, while pursuing his Masters in Bioelectrical Engineering at McGill University, he formed a team that combined engineering and technology to develop microsolutions. Some of those initial microsystems are the foundational components used by the three companies that Charles founded: MY01, Inc., Stathera, Inc., and  NXTSENS Microsystems, Inc. These companies each have won several awards and been selected for important growth accelerators. They have grown to over 70 employees, and combined to raise over $50M in funding.

Dr. Aggarwal has been internationally recognized for his work in advanced heart failure and structural heart disease. His clinical areas of interest include mechanical circulatory support, cardiac transplantation, ECMO, minimally invasive and transcatheter valve repair and replacement, and complex re-operative procedures. He has served on multiple institutional and national committees and scientific advisory boards. He has authored and co-authored numerous peer-reviewed articles, abstracts, and book chapters, and has been a principle or co-investigator in several FDA-approved clinical trials.

Prior to joining Abiomed, Dr. Aggarwal served as the Chief of Cardiovascular Surgery and the inaugural Clinical Innovation Officer for Beaumont Health in Michigan.  He previously was the Director of Cardiac Transplantation and Mechanical Circulatory Support at Saint Luke’s Mid America Heart Institute in Kansas City, MO.  Dr. Aggarwal has also held faculty appointments in the Department of Surgery at Columbia University- New York Presbyterian Hospital and the University of Louisville Medical Center.

Dr. Aggarwal earned his undergraduate degree at the University of Pennsylvania, majoring in biology and minoring in chemistry and economics. He earned his medical degree from the Baylor College of Medicine in Houston, TX.  Dr. Aggarwal completed his residency in general surgery at NYU Medical Center, and then attended the University of Michigan for his cardiothoracic surgical training.  While at the University of Michigan, Dr. Aggarwal was the recipient of a research training grant from the National Institute of Health (NIH). He also completed an advanced cardiac surgical fellowship in heart transplantation, ventricular assist devices, and minimally invasive surgery at Columbia University-New York Presbyterian hospital in New York.  More recently, Dr. Aggarwal has earned an M.B.A. with certification in data science and business analytics from the Sloan School of Management at the Massachusetts Institute of Technology.

Mr. Anand believes in the empowerment of patients with clinically relevant and AI driven biomarkers. As the Vice President and Head of Digital Biomarker Solutions at Lantheus, he is responsible for executing the value-based adoption strategy of AI-enabled biomarkers to deliver better outcomes for patients with prostate cancer. His 20 years of industry experience has allowed him to gain core competencies in product development, regulatory approval, and commercial launch of novel digital biomarkers for radiopharmaceuticals. Prior to industry, Mr. Anand had eight years of academic and research training in Genitourinary Oncology at Memorial Sloan Kettering Cancer Center. He received his doctorate in Translational Medicine at Lund University, Sweden, and holds a graduate degree in biotechnology at Columbia University, New York, USA.

Liz Asai is an expert in digital health startups, software as a medical device (SaMD), and early commercialization of new healthcare technology. She currently serves as Hologic’s Global Head of AI & Connectivity, spearheading their effort to develop AI solutions for breast and skeletal applications worldwide. Liz began her career co-founding 3Derm, a teledermatology and skin cancer AI company. She raised several rounds of capital, attracted over a million dollars in public and private research grants, and successfully advocated for reimbursement of 3Derm’s telemedicine service from several major payers. In 2020, 3Derm obtained FDA Breakthrough Designations for two autonomous AI skin cancer detection algorithms and was acquired by Digital Diagnostics. Post-acquisition, Liz served as VP of Strategic Development at Digital Diagnostics overseeing pre-market development of their pipeline of ophthalmology and dermatology AI products. Liz holds a bachelor’s degree in Biomedical Engineering from Yale University.

 Dr. Anna Barnacka is the CEO and founder of MindMics,the actionable health monitoring company. MindMics hasinvented a breakthrough in precision monitoring tocapture unique human audiome health data through in-ear headphones. Anna finished her NASA EinsteinFellowship at Harvard in 2018 and has a track of leadingdiverse and pioneering teams that solve intractableproblems by working at the leading edge of signalprocessing, data analysis, numerical modeling, softwaredevelopment, and infrastructures and instrumentations.Anna has a dozen patents to her name related to in-earinfrasonic hymodynography. In addition to herbreakthrough innovations, she has co-authored morethan 90 peer-reviewed scientific publications onastroparticle physics, black holes, and, in particular, thephenomena of gravitational lensing. She pioneeredtechniques for turning gravitational lenses into high-resolution telescopes. In her free time, she enjoys martialarts, in particular traditional karate in which she is a blackbelt, and her role as Chief Scientific Officer of theMultiverse Concert Series, where she acts as ScienceDirector of Black Hole Symphony.

Henrik is Senior innovation Lead located in Boston in the Bio Innovation Hub on Kendall Square. Henrik was working in Novo Nordisk for 22 years and have received a lifetime award for producing +100 Patents. This has been done together with his team including many PhD- & Post.doc- students.  Prior to entering the medical device field, Henrik invented a new type of amplifier and was part of starting up the company Bang & Olufsen ICEpower A/S focused on bringing professional Audio solution to market.

Dr. Jon Bloom is a board-certified physician and entrepreneur with over 20 years of experience in technology development, patient monitoring, biomedical research, and health care delivery. He co-founded Podimetrics in 2011 while a student at the MIT Sloan School of Management, and he’s served as our CEO ever since. Dr. Bloom was first inspired to create a solution to help prevent diabetic amputations while practicing anesthesia; he frequently treated patients who required foot amputations and knew there had to be a less drastic way to prevent diabetic foot complications. He previously served as a Clinical Assistant Professor and staff anesthesiologist at the University of Pittsburgh Medical Center, and as the Director of Global Medical Affairs for Covidien’s Respiratory and Monitoring Solutions division. Dr. Bloom has co-authored more than 20 peer-reviewed publications with a primary focus on health care economics and perioperative complications. He earned his medical degree from the University of Pittsburgh School of Medicine and completed his residency at Massachusetts General Hospital. 

Pamela is an accomplished Business Executive with an exceptional 30 year career history leading the growth of medical devices and software in some of the world’s most respected organizations, including GE Healthcare and Envista Dental Holdings. With her expertise in strategic planning and execution, she has managed P&L’s ranging from $1 00M to $850M in revenue. Her unparalleled leadership abilities and business acumen were recognized when she was recruited by Danaher Corporation to help lead the spin-out of their dental business platform as Envista Dental Holdings, which successfully launched as an IPO on the NY Stock Exchange.

Pamela is an influential and dedicated board member, making a profound impact on transformative organizations. As Board Chair of HerHealthEQ, a nonprofit dedicated to creating health equity for women in developing communities worldwide. She brings her industry expertise to support the acquisition of essential medical equipment for detecting, preventing, and treating non-communicable diseases, she actively contributes to their mission. At BACCH Laboratories, she harnesses her exceptional AI and commercial acumen to propel the revolutionary expansion of their cutting-edge sound technologies, spearheading the advancement of hearing aids to empower those with hearing loss. She leverages her wealth of commercial expertise to expedite OUTCOMEUS’s progress in fulfilling their mission to enhance the well-being of individuals afflicted by chronic pain. Most recently she joined Proove Genomicsis a molecular diagnostics company delivering on the promise of precision pain medicine based on its award-winning history and research.

Pam has a proven track record of developing and leading the profitable growth of businesses throughout North America, thanks to her strong commercial foundation built during her 26-year tenure at GE Healthcare. Her contributions have earned her a place in The Top Women in Medtech to Know. With her expertise in developing commercial excellence, datadriven decision making, assessing product viability, and marketplace trends, she has helped numerous organizations achieve impactful go-to-market strategies.

As the CEO of Ultrasound Al, she transformed a startup into a well-structured organization poised for success, with a focus on product development, regulatory compliance,commercialization and operational excellence. Under her leadership, the team successfully submitted the first product for FDA clearance with expected clearance in 2024.

Outside of work, Pam enjoys golf, biking, boating, and all things outdoors. She is a Chicago native who raised her three children there and now resides in Naples, FL with her husband, regularly traveling between the two cities.

Gabriele Brambilla, MBA, is Alira Health’s Chief Executive Officer and Co-Founder. As CEO, Gabriele evangelizes Alira Heath’s mission—humanizing healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance.

 In 2018, he co-founded the MetroWest Life Sciences Network, a regional collaboration of healthcare and life science-based organizations, municipalities, and economic and business development organizations in Boston’s MetroWest, where Alira Health is headquartered. As the network’s current chairman, Gabriele fosters collaboration, innovation, and entrepreneurship in this critical life sciences ecosystem.

 He is also on the Board of Directors of MassMedic, EnlightenVue, WoundForce, Firefly Innovations, X-Cor Therapeutics, Computational Life, SMOC, and the co-founder of Inter Academy MetroWest Boston soccer program.

 Gabriele began his career in pharmaceuticals, working for an Italian firm based in Shanghai, and developed his deep industry expertise through roles with medical device and digital health technology practices.

 He holds a BA in Political Science from the University of Pavia, a master’s degree in International Affairs from the I.S.P.I., and an MBA from Post Graduate SDA Bocconi in Milan, Italy.

Nikki is a seasoned commercial executive with over 20 years of invaluable experience in women’s healthcare. Throughout her career, Nikki has made significant contributions to both pharmaceutical and medical device companies, demonstrating expertise in commercializing medical devices, developing marketing strategies, and fostering resilient, sustainable cultures within organizations.

With a steadfast dedication to improving healthcare for women and infants, Nikki has been instrumental in driving initiatives aimed at enhancing accessibility, quality, and innovation in this critical area of healthcare. Her wealth of experience and leadership skills have enabled her to navigate complex challenges and spearhead transformative strategies that positively impact patient outcomes.

Nikki’s passion for championing the well-being of women and infants extends beyond her professional endeavors, as she actively engages in advocacy efforts and collaborations aimed at advancing healthcare equity and access on a global scale.

Dr. Christopher Buller graduated from University of Western Ontario, Cum Laude, and pursued his training in Internal Medicine and Cardiology at the University of Toronto and University of British Columbia. His fellowship in Interventional Cardiology under Richard Stack at Duke University led to a career-long interest in the development and validation of cardiac devices. After training, Dr. Buller returned to the University of British Columbia and its teaching hospitals, eventually leading the Division as the U.B.C. Sauder Chair in Cardiology. In 2009 Dr. Buller joined the renowned cardiac program at St. Michael’s Hospital as Director of Cardiac Catheterization and Intervention and Professor of Medicine, University of Toronto. After a decade leading both advanced coronary and structural heart intervention teams, he accepted a position at Teleflex as Medical Director, Interventional. Now focused on device development, he nevertheless has continued his practice in complex coronary intervention – a connection he believes central to solving for true clinical needs.

Mr. Calef is a highly accomplished medical roboticist and seasoned engineering leader who has delivered breakthrough innovation in surgical robotics. Previously, he was the Director of Advanced Robotics at Medrobotics, where he led the development and release of the first flexible surgical robotics platform, grew the engineering team from two to 50 people, and guided numerous surgical robotics products through 510k clearance. He holds both a B.S. in Computer Engineering and a M.S. in Mechanical Engineering from the University of Massachusetts.

Jay Caplan is Co-founder, President, and Chief Product Officer of Fractyl Health and has held leadership positions in the medical device field for more than 20 years.

Prior to founding Fractyl Health, Jay was the Chief Operating Officer of the Candela Corporation, a world leader in aesthetic devices. Previously, he was Chief Technology Officer and Vice President of Research and Development at InfraReDx, Inc. a venture-backed startup developing a novel cardiovascular imaging system to identify lipid-rich coronary plaques.

Prior to InfraReDx, Jay was Vice President of Operations for Thermo Cardiosystems, where he led the team developing the HeartMate II left ventricular assist device. Jay holds a B.S. in electrical engineering from M.I.T. and an MBA from The Wharton School of the University of Pennsylvania.

Michael H. Carrel has served as President and Chief Executive Officer of AtriCure (NASDAQ: ATRC) since November 2012. AtriCure, Inc. is a medical device company that provides innovative solutions for surgical treatments and therapies of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. AtriCure’s mission is to reduce the global Afib epidemic and heal the lives of those affected.

Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on three core areas: innovation, clinical science, and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials, expand its market presence within Europe and Asia and grow the global employee base from 200 to over 1000 employees. During Michael’s tenure, AtriCure has acquired three companies (Estech, nContact, and SentreHEART) adding leading ablation and left atrial appendage management technologies to further AtriCure’s market position worldwide.

His career includes successful leadership in global organizations in the healthcare and technology industries. Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly traded medical imaging software company. He led Vital Images to a global leadership position in the healthcare and medical software industry. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and lead the company through a sale to Toshiba Medical Systems Corporation. Prior to joining Vital Images, Michael was President and CEO of Zamba Corp., a publicly traded technology company, and Chief Financial Officer of NextNet Wireless, a privately held provider of non-line-of-sight plug and play broadband wireless access systems.

Mr. Carrel serves on the Board of Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc., and serves as National Board Chair of Big Brothers Big Sisters of America. Michael earned a bachelor’s degree in accounting from Pennsylvania State University and a master’s degree in business administration from the Wharton School at the University of Pennsylvania.

Margi Coggins is a certified nurse-midwife with over twenty-five years of experience in women’s health. She “caught” more than a thousand babies in both hospital and community settings. She was an International Board Certified Lactation Consultant and helped the Cambridge Birth Center apply for Baby Friendly designation. She directed one of the largest midwifery practices in Massachusetts at Mount Auburn Hospital for almost a decade. She helped start families with alternative insemination and continued to see those moms for their annual exams for years afterwards. She taught medical, nursing and midwifery students in the clinic and at the bedside.

Margi left clinical practice in 2022 to “midwife the system” of obstetrics throughout the Commonwealth. She has been a member of the Massachusetts Mortality & Morbidity Review Committee since 2015 and serves as President to the Massachusetts Affiliate of the American College of Nurse-Midwives. She also provides consultative services to medical product designers. She received her MSN from the University of Missouri, her BSN from Rockhurst University/Research College of Nursing, and her BA in Biology from Mount Holyoke College. She also earned an MS in Entomology from Michigan State University.  When she isn’t doing “work-work,” she does “farm-work” at her family’s small off-grid farm in Western Massachusetts where she keeps bees and chickens, makes wine and maple syrup, and picks about 2 tons of rocks each year.

Marissa Fayer is a 20+ medtech executive, innovator, entrepreneur, investor, and philanthropist. She is the CEO and founder of non-profit HERhealthEQ, CEO of DeepLook Medical, Entrepreneur-in-Residence at Graybella Capital, and Co-Chair of the US AI for Good Innovation Factory.  Her mission is to move innovation and the health of women forward throughout the world.

Through her work with DeepLook Medical, Marissa has commercialized the FDA-cleared technology with 4 commercial sales and distribution partnerships, raised $2M in Seed capital, has increased publicity of the company by being featured in Forbes, FemTechInsider, and FemTechWorld, and has spoken at some of the largest healthcare conferences in the world.  Though her work with HERhealthEQ, Marissa has led the organization to improve the health of 41,000 women in 9 different countries around the world.  Her leadership has built the board, deployed 35+ pieces of equipment, won the PIR .Org Impact Health award in 2023, and led the fundraising efforts to support the treatment, detection, and/or prevention of breast cancer, cervical cancer, and maternal health for women globally.

Marissa has previously served as an executive at Hologic, Olympus (formerly ACMI), Maquet-Getting (formerly Atrium Medical), Providien Medical, and Accumed Innovative Technologies.  Her consulting clients include many of the Top 500 healthcare companies and innovative start-ups including Pfizer, Boehringer Ingelheim, Nuvasive, the National Institute of Health (NIH), Oerlikon Medical, Lonza Precision Medical, Emit Imaging, and others.   Marissa sits on the board of medtech companies Welwaze Medical and DeepLook Medical both focused on improving the diagnosis of breast cancer; and an Advisor to Impact.51 which is an Israeli accelerator focused on women’s health.  Marissa graduated from Boston University with a BS in Manufacturing Engineering, from University of Connecticut with an MBA, and from the IESE Business School in Barcelona of the Global Health Innovation Management program.

Marissa is a TEDx Speaker (2019 at TEDxLugano), a UCSC Miller Center Social Entrepreneur Fellow, and has been listed as one of the Top 100 Women in Medtech, a 2024 MedTech Voice to Watch, a First in FemTech award winner in 2022,  awarded the Africa Development Award, a Wonder Women in Medtech, and has delivered keynote discussions at some of the leading global healthcare conferences around the world.  Marissa has appeared in several publications such as Forbes, FemTechWorld, FemTechInsider, Medical Design & Outsourcing, BloombergLaw, FemTech Analytics, the Maven Collective, Med Device Online, Citeline Commercial, and TheStreet.com.  Marissa is dedicated to innovative solutions for global women’s health throughout the world.

Marissa lives in New York City and can be found at www.marissafayer.com

Diana Gelston is the chief commercial officer of Best Buy Health for Best Buy Co. Inc. In her role, she is responsible for building and strengthening the company’s commercial relationships that aim to enable care at home for everyone.

Diana leads a large, diverse team in creating and executing high-impact, go-to-market strategies that support the company’s mission to enrich and save lives through technology and meaningful connections. At Best Buy Health, she is focused on developing integrated commercial strategies that support consumers wherever they are on their health journey and improve the care-at-home experience.

Previously, Diana has successfully launched and developed more than a dozen sales and marketing teams, with P&L’s of more than $2.1B, in tech, medical devices, digital health, and healthcare information systems at Amazon Business Healthcare, Fresenius Medical Care, Philips Healthcare, and other innovative start-ups.

Diana earned a bachelor’s degree from the University of Southern California and a certificate in Leadership Development and Business Administration from the University of Pennsylvania’s Wharton Business School.

Yael is the VP of Business Development and Strategy for the Medtronic Diabetes. Previously, Yael was the CEO of nutrition science startup, Nutrino Health where she led the company to a successful acquisition by Medtronic in December of 2018. Before Nutrino, Yael held multiple commercial roles in healthcare technology companies, including VP of Business Development at Sensible Medical, VP Marketing and Strategy at telemedicine leader, AmWell and Director care management marketing at TriZetto (acquired by Cognizant). Yael also serves on the board of directors of Grin, a tele-dentistry company and she is an angel investor in startup companies. Yael holds a BA in Psychology from Hebrew University and an MBA from MIT Sloan of Management.

Andrew Greenfield, Abiomed’s worldwide president, has served in a leadership capacity at Abiomed since joining the company in 2005, including serving as a Section 16 Officer and named executive officer of Abiomed. Before being appointed president in 2022, Andrew served as executive vice president and chief commercial officer for four years.  Prior to that, he was vice president and general manager of global healthcare solutions.

Before joining Abiomed, Andrew held positions in sales, marketing and finance at GE Healthcare and The Boeing Company.  Andrew has served as chairman and executive committee member for MassMEDIC, a public-private partnership that coordinates resources used in managing medical devices to improve patient access to cutting-edge medical technology. He is also a past executive committee member with the Medical Device Innovation Consortium (MDIC), which is advancing safer and more cost-effective innovations to benefit patients.

Andrew holds a bachelor’s degree in finance from the University of Illinois and a Master of Business Administration degree from St. Louis University.  He is also a certified Master Blackbelt in Six Sigma and Change Acceleration Process from GE.

Dr. Nan-Wei Gong is a serial entrepreneur, technologist, and digital health innovator. She is the founder & CEO of FIGUR8 Inc, the industry leader in transforming musculoskeletal (MSK) care with objective data and AI-driven biomarkers. She is also a research affiliate at the MIT Media Lab.

Throughout her entrepreneurial journey, Dr. Gong has amassed valuable experiences, beginning with her role as the co-founder of 3dim Tech, which specialized in gestural control for mobile devices—a company that was later acquired by Google. She founded Circular2, an engineering consulting firm, boasting a client roster that includes institutions such as MIT and Harvard, as well as industry giants like Google, Microsoft, and Samsung.

Dr. Gong received her BS/MS in Materials Science Engineering from NTHU and her PhD from the MIT Media Lab. As an innovator driven by rigorous scientific and engineering training, she has published over 30 peer-reviewed papers including best paper awards at top ACM conferences, and has filed and been granted over 10 US patents to date.

Rachel Hall is a seasoned Senior Global Strategic Marketing Manager that is focused on bringing Biologic and Biomaterials solutions to the Orthopedic market.  Much of her time is spent assessing these technologies to ensure they address the unmet needs healthcare professionals and their patients.  She currently works for DePuy Synthes, a division of Johnson & Johnson MedTech.

With 20 years of experience in the healthcare industry, domestically and abroad, Rachel is practiced at navigating and executing within complex environments including cross-cultural, cross-functional, and strategic partnerships.  She has launched over 20 technologies within Spine, Vascular, Renal, and Pulmonary therapies leveraging new product development, mergers, acquisitions, and licensing best practices.  She has worked in supply chain, payer coverage and reimbursement, marketing, and international development at large and small, for-profit, and non-profit, organizations.  She holds a MSc. in International Marketing from Boston University and a BA in Biological Sciences from the University of Chicago.

A public relations expert known for making the hard parts easier, Kate Haranis has successfully earned thousands of meaningful media placements, ghostwritten hundreds of bylines and speeches, and trained dozens of senior and rising executives in effective, authentic storytelling. After nearly two decades building effective, action-oriented communications in Fortune 500, nonprofit and agency roles, Kate founded Haranis & Company help clients with life-changing businesses accelerate innovation through powerful communication.

From her start at Dana-Farber Cancer Institute to her most recent role leading corporate PR at Boston Scientific, Kate shines when crafting stories that move audiences past awareness to inspire action.

Kate’s experience spans nonprofit development, independent PR agencies and in-house corporate communications. Put another way, years offundraising, media relations and businessdevelopment didn’t just teach her to redirect rejection—they honed her ability to move stakeholders to yes.

Kate’s advocacy and philanthropic experience includes serving on the executive board of the Children’s Trust of Massachusetts and past leadership roles with the Environmental Business Council and Junior League of Massachusetts. She has also served as professional mentor to the Public Relations Student Society of America Emerson College chapter, and enjoyed additional engagements with 826 Boston, the Massachusetts Society for the Prevention of Cruelty to Children and The Home for Little Wanderers. She received her Bachelor of Science in political communication, magna cum laude, from Emerson College.

When Kate isn’t working, having family dance parties, or connecting with friends, she’s probably headed to or from Pilates. 

Addie Harris has a robust history of entrepreneurship in software, medtech, medical devices, and robotics. She is currently CEO of Haventure, a robotics and digital technology incubator, and holds board  and advisory roles with over a dozen companies, including  Visie Vision Inc., SPINEM Robotics, MRI Guidance, Nurture by Naps and others. Previously, she served as founder and CEO of Cardan Robotics (acquired by Stryker in 2019) and has held roles at well-known robotics endeavors. Ms. Harris was an R&D leader at Johnson & Johnson, founding the orthopedic robotics organization, acquiring Orthotaxy, and leading the VELYS Robotic Surgical Solution through development to commercial launch. She holds an MS and BS in Mechanical Engineering from Tufts University and an MS in Computer Science from Lincoln University in New Zealand, where she was the Fulbright Distinguished Fellow in Robotics, Augmented Reality and Computer Vision.

Dr. Anh Hoang-Lindsay is the CEO of Jana Care Inc, a pioneering developer of at-home, self-administered blood testingtechnologies for heart disease and chronic kidney disease management. The platform enables patients to self- administered blood tests at-home and allows clinicians to review the test results remotely as needed. Prior to Jana Care, she was the founder of Sofregen Medical, a company that is re-inventing ancient silk technologies to restore loss of tissue volume. At Sofregen, Anh operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen received the first FDA cleared product made from reconstituted silk protein for the treatment of vocal fold insufficiency.

Outside of Sofregen, Anh is a part time faculty at MIT’s Catalyst Program and serves as an advisor to several early stage companies. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators. Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Mass General Hospital as an Executive Committee on Research fellow.

Dr. House is a Professor of Obstetrics and Gynecology at Tufts Medical Center, where he specializes in high-risk obstetrics. He graduated from the University of California, San Diego School of Medicine and completed his residency at Los Angeles County/USC Hospital. He then pursued a fellowship in Maternal Fetal Medicine at Tufts Medical Center and joined its faculty after finishing his training. Dr. House conducts research on preterm birth and cervical dysfunction, with funding from the Society of Maternal Fetal Medicine, the March of Dimes, and the NIH. He has published 60 papers on topics related to high-risk obstetrics.

Twenty-two months ago, Mike Hugo was faced with a daunting diagnosis: Glioblastoma. But instead of bowing to this challenge, he faced it with the same tenacity and spirit that has characterized his whole life.

Not only is he a loving husband to Vanessa and a devoted father to his two young daughters, aged 7 and 9, but his professional journey in the medical device industry, covering esteemed roles at Medtronic, Stryker, and NuVasive, has been marked by significant achievements. His contributions span engineering, marketing, sales, and sales management, demonstrating a commitment to innovation that has resulted in several vital patents in medical device development.

Mike is the embodiment of adventure and competitive spirit. He has completed 11 full Ironmans, participated in 30-40 marathons, piloted stunt planes, and even embraced the sky as a skydiver, showcasing an unyielding zest for life and a refusal to be defined by limitations.

Mike is not only surviving but thriving, thanks to the advancements in medical technology. His journey brings a new perspective on life and work, transforming the daily grind into a daily opportunity for growth and impact. He extends a heartfelt thanks to the medical community that has supported him and often offers unique insights into the profound impact of our industry’s work from the perspective of a patient, a professional, and an indomitable spirit.

Caroline Irungu is a Global Commercial Strategist for medical devices and diagnostics at Dassault Systémes. Caroline joined Dassault Systémes from Stryker where she led efforts to drive change for more sustainability in healthcare including leading product launches for products specifically designed for sustainability. Prior to Stryker, Caroline was a Director of Product Management at Zimmer Biomet where she led the Extremities business. Earlier in her career, at Medtronic, Caroline had extensive experiences leading global product launches and driving adoption of new medical technologies. She began her career as an R&D engineer where she learned her love of the operating room and partnering with surgeons to make an impact on patients. This led her to a long career in sales where she provided support to surgeons across many cardiovascular therapies. Caroline earned her bachelor’s degree in Biomedical Engineering from Stevens Institute of Technology, and her Master of Public Policy degree from New York University.

Brian Johnson was named president of the Massachusetts Medical Device Industry Council (MassMEDIC) in July 2018. An accomplished author, media entrepreneur, Brian serves as the  association’s second chief executive officer in its history, managing its day-to-day operations and working with medical device industry executives in developing its policy agenda. Since its establishment in 1996, MassMEDIC has grown to 300 member companies – manufacturers and developers of medical products, suppliers, research institutions and academic health centers –  and has advanced the public policy interests of the New England medical device sector on Capitol Hill, Beacon Hill, and before various federal agencies. 

In 2007, Brian conceived and later launched MassDevice.com, where he been responsible for the strategic vision of the company, from inception through the summer of 2018, including leading the company through an acquisition in 2015 by WTWH Media.     

As publisher, Brian spearheaded the growth of MassDevice from 0 to 100,000+ readers each month and led the company to profitability in just 3 years and more than $2.8M in annual sales. In 2011, Brian conceived and launched DeviceTalks, a live-interview series featuring leaders in medicine. The event, which is held three times annually in Boston, Minnesota and Orange County, California, has attracted thousands of medical device executives to date and featured leaders from some of the world’s largest medical technology companies. Since 2015, Brian also founded and launched two additional magazines, Medical Design & Outsourcing and Drug Delivery Business News, bringing total readership under his supervision to over 1.5 million.  

Under Brian’s direction, MassDevice and its associated properties were widely recognized for its commitment to quality journalism. The editorial boards of the New York Times, NPR, Wall Street Journal, Washington Post have cited MassDevice’s coverage of issues pertaining to the medical device industry.  In 2012, MassDevice won a prestigious Communicator award in 2012 for excellence with its live web video series “Disruptors.”  

An experienced reporter and author, Brian has worked for The Associated Press, Boston Globe digital and The Eagle-Tribune newspaper, covering business and economics, local government and crime.  In 2017, his critically acclaimed first novel “MWD: Hell is Coming Home” was released by Candlewick Press. 

Brian resides in Brookline, Massachusetts with his wife and two young children.  

​

​

For more than 30 years Tom has been a key member of the Skeletal Health R&D team at Hologic, developing a wide variety DXA applications for both clinical medicine and research. His interests include reference data, pediatric densitometry, body composition, visceral fat, and other high resolution fan beam applications.  He holds more than a dozen U.S. patents in densitometry and adjacent spaces and is perhaps best known as a co-developer of the T-Score for the diagnosis of Osteoporosis.

Matt’s engineering background and deep knowledge of arthroscopic techniques has positioned him to be considered an industry expert in design and development of Sports Medicine products.  During his 20 years at S+N,  Matt has led the development and successful commercialization of multiple generations of implants and instrumentation serving knee, shoulder and hip patients.  He holds more than 25 granted US patents with over 20 more patent applications currently pending. His technical knowledge and involvement in M&A has been critical in early diligence and successful integration of acquisitions including ArthroCare, Rotation Medical, Ceterix and CartiHeal.

Srinivas has over 25 years of experience which spans across Consumer Electronics, Biomedical Instrumentation and Medical Imaging. He has led research and development teams, focused on end-to-end 3D/4D quantification applications and released several “concept to research to market” solutions. He also led a cross functional team to drive applied research, product development, human factors team, clinical research, external collaboration and innovation

 He has garnered diverse sets of skill sets and problem challenges and has over 25 Patent filings and 15 Patent Grants across varied domains, mentored over 30+ student projects, been a guide for over 10+ master thesis students, peer reviewer for papers and an IEEE Senior Member (2007).

Jessica Lavoie is an accomplished marketing leader with over a decade of experience in the dynamic world of digital healthcare startups. She specializes in delivering effective marketing and communication solutions for organizations focused on utilizing technology to enhance patient outcomes. As the Head of US Marketing at Healthy.io, she leads the US team in creating and executing strategic campaigns to drive adoption at scale for two unique product offerings – Minuteful Kidney and Minuteful for Wound. With a track record of bringing FDA-cleared products to the US market, Jessica collaborates closely with international partners, national organizations, large payers, and healthcare systems to commercialize these groundbreaking technologies.

Under her leadership, Healthy.io’s smartphone-enabled diagnostic tests and digitized wound care services have facilitated over 1 million patient assessments globally.

Before joining Healthy.io, Jessica spearheaded marketing efforts at Cricket Health and Binx Health, demonstrating her dedication to advancing patient-centric care. Her focus included populations at risk of chronic kidney disease and developing on-demand testing for improved patient accessibility. Jessica holds a BA in Communications from Suffolk University.

Jennifer Law leads maternal health partnerships at Philips, a leader in healthcare technology that aims to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. Jennifer champions innovative solutions—from remote fetal/maternal monitoring, to portable and AI-guided ultrasound, to the world’s most downloaded pregnancy app—to help close the care gap for millions of pregnant women who lack access to quality prenatal care in the U.S. and around the world.

Beyond her primary role, Jennifer is an active member of the HHS Maternal Mental Health Task Force, serving a two-year term where she applies her expertise to improve mental health care for mothers.

Prior to joining Philips, Jennifer was a consultant and award-winning book author, earning recognition from Consulting Magazine as a “35 under 35” Rising Star in 2021. Jennifer’s global perspective is enriched by her experience as a Fulbright Scholar in South Korea, a program run by the U.S. State Department. This experience, along with her professional achievements, underscores her commitment to improving healthcare equity worldwide.

Jennifer is a graduate of Williams College and mom to two young children.

Monique’s background uniquely combines training in clinical psychology with deep experience developing corporate strategies and commercial traction for some of the world’s most innovative data, digital health and therapeutics businesses. Her track record includes executive-level positions at leading bio, data and consumer health technology companies, where she worked with top scientists and technologists to develop novel products and innovative commercial partnerships. Before joining Woebot Health, Monique was Chief Strategy Officer at the precision CNS biotechnology company BlackThorn Therapeutics, where she led corporate and platform strategy, and corporate development. Before that she was Global Head of Strategy, Partnerships and Products at the precision medicine company iCarbonX Group. Monique has also held executive level positions at PatientsLikeMe and Decision Resources Group, and served on Google Health’s Advisory Board.

Dr. George Lewis is a Biomedical Engineer, Mechanobiologist and Neurobiologist in Regenerative and Sports Medicine. He serves as the Chair or Rehabilitation Medicine Research for the United States Veterans Health Administration since 2020, and Board Member for the Orthopedic Foundation since 2017. Prior to founding ZetrOZ during is doctoral studies in early 2007, Dr. Lewis trained at Cornell University 2006 and the University of Miami 2002. Dr. Lewis has been a US Presidential Research Fellow, Life Science Innovation Fellow, and Principal Investigator on multiple federally funded medical development programs by the NIH, DOD, NASA and NSF, and has commercialized numerous medical innovations into the global healthcare system over the last 2-decades.

Dr. Lewis has considerable experience in ultrasound miniaturization, wearable electronic systems, and the study of biological effects of ultrasound on tissue. In his career, three of the notable contributions to science are: 1) Demonstrating the safety of daily long-duration ultrasonic stimulation to biological tissues, 2) Studying the mass transfer phenomena of ultrasound on molecules and nutrients in poroelastic biological tissues, and 3) Establishing designing principles behind ultrasonic systems using ultralow-impedance electronics and transducers.

Dr. Lewis has been recognized for leadership and engineering innovation, and has been featured by the NSF, NIH, DOD and other government and private granting organizations for biomedical research and commercialization. In June of 2020 Dr. Lewis was invited to present the last decade of translational mechanobiological ultrasound research at the NIH Pain Consortium Symposium. In March of 2022 ,Dr. Lewis was invited to present on non-opioid technologies for the NFL medical staff at the Indianapolis Combine.

Beyond research, development and global healthcare innovations Dr. Lewis is an avid instrument and jet-rated pilot, hockey and volleyball player, and husband and father of four. In his free time Dr. Lewis enjoys attending athletic events and hiking in the White Mountains of New Hampshire.

Dr. Trang Ly has served as the Senior Vice President and Medical Director at Insulet since February 2018. From September 2016 to February 2018, she served as our Vice President and Medical Director. Dr. Ly is a renowned expert in artificial pancreas and diabetes technologies. Most recently, she served as Clinical Assistant Professor in the Division of Pediatric Endocrinology, Stanford University School of Medicine. Prior to her time at Stanford, Dr. Ly was a Pediatric Endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. Dr. Ly holds a Bachelor of Medicine and Surgery, a Diploma of Child Health and a PhD in Pediatrics from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians, with specialist qualification in Pediatric Endocrinology.

Tracy MacNeal is the CEO of Materna Medical. She is a chemical engineer, a Duke MBA, a healthcare entrepreneur, and a medical technology investor. A driver for health equity, Tracy also serves on the Board of Directors for AdvaMed, the national industry organization for medical devices, and leads their Women’s Health Equity Initiative. Tracy is President and CEO of Materna Medical, a novel, post-revenue OBGYN company with one product on the market and an exciting clinical stage product seeking to reduce maternal injury, shorten delivery time, reduce C-sections, and improve postpartum recovery for new moms.

As the leader of robotic and digital surgery technology at Cambridge Consultants, Alex guides teams in developing groundbreaking products to shape the future of healthcare. His work is focused on identifying high value opportunities for clients and creating novel solutions for an increasingly digital future. Alex specializes in realizing winning competitive strategies in highly uncertain environments through a systematic approach to innovation. His technical experience ranges from computer vision algorithms and novel robotic manipulators to connected digital platforms.

Sean Messenger is Director of Product Operations for Medtech Insights products at Clarivate, a global leader in trusted and transformative intelligence. In this role Sean has cultivated more than a decade of experience working with the world’s top medical device firms to use data, analytics, and insights to solve their problems. Sean’s experience includes developing and executing product strategy for healthcare data and analytics solutions, directing operations and customer engagement to deliver large-scale market intelligence projects, and leading a global team of analysts responsible for monitoring, analyzing, and reporting on medical device trends.

Previous speaking engagements include the HIDA Streamlining Healthcare Expo, the Life Sciences Forum in Costa Rica, and multiple briefing sessions on cardiovascular medical devices during ACC and TCT conferences in partnership with Bloomberg Intelligence.

Sean holds and Honors BSc from the University of Waterloo with a specialization in biotechnology and a minor in economics.

 Michael Minogue is the President and CEO of Minogue Consulting, LLC. and Heartwork Capital, with over 30 years of industry experience leading with his “Patients First” and “Dream Big, Execute Bigger” mindset. By training individuals how to adapt, execute, lead, and manage, Michael empowers and inspires people to achieve their best results with integrity, creativity, intellect, and grit. 

For nearly 19 years, Michael served as Chairman, President, and CEO of Abiomed, Inc. (NASDAQ: ABMD), which revolutionized the field of heart recovery through the development of Impella®, the world’s smallest heart pumps. He devoted himself and the company to recovering hearts and saving lives, leading in technology and innovation, growing shareholder value, and sustaining a winning culture. This culture and vision led Abiomed, Inc. to be one of the fastest growing, GAAP profitable MedTech companies, generating total shareholder return of 2,467% since April 2004 and 1,172% in the last 10 years. 

Under Michael’s leadership from 2004-2022, Abiomed, Inc. treated over 250,000 patients, received multiple exclusive FDA approvals, expanded their patent portfolio to over 2,000 patents and over 2,000 pending, increased revenue from $22M to $1.2B, and grew market capitalization from $170M to approximately $17B. His tenure culminated in negotiating with Johnson & Johnson, resulting in the largest all-cash acquisition in MedTech history (16.9x EV/Revenue | 64.4x EV/EBITDA) and the 7th largest MedTech deal of all time. 

Prior to Abiomed, Inc., Michael spent 11 years with General Electric Healthcare, leading in roles of sales, marketing, product development, engineering, software, and services. While there, Michael filed three patents. He also served as an Infantry officer in the U.S. Army, where he earned multiple distinctions including Airborne, Ranger, and Bronze Star as the lead navigator and Platoon Leader for the 24th Infantry division in Desert Storm. Michael received his B.S. in Engineering Management from the United States Military Academy at West Point and his M.B.A. from the University of Chicago. 

Michael currently serves on the boards of Insulet Corporation (NASDAQ: PODD), St. John’s Preparatory School, Crane Estate Advisory Board, and MedTechVets. In addition, Michael is a co-owner of BOOST Oxygen and serves as General Partner for Essex Woodlands. Previously, Michael served on the board of the medical device industry association, Advamed (2007-2023) and as Chairman (2021-23). He has also served on the boards of LifeCell, Bioventus, and Medical Device Innovation Consortium, (MDIC, Chair-2016-19). 

Michael is passionate about supporting education, military veterans and causes for children. In 2012, Michael co-founded MedTechVets, a 501(c)(3) nonprofit organization that helps military veterans discover career opportunities in MedTech. In 2015, he co-founded the Mike and Renee Minogue Foundation to support faith-based education and pediatric care through partnerships with the Catholic Schools Foundation, WonderFund, Boston Children’s Hospital, and multiple others. 

Michael is married with five children and enjoys reading, running, coaching, and skiing. 

Joe Mullings has been building companies and careers since 1989. He is the Founder, Chairman and CEO of The Mullings Group, including TMG Search and Dragonfly. The search firm, with over three decades in the industry, is responsible for more than 9,000 successful searches in medtech / healthtech / life sciences with clients ranging from multi-billion-dollar companies to emerging high-tech organizations worldwide. TMG’s international presence and work with over 900 companies allow them to provide solutions to the clients they partner with across the globe.

As the first search firm to integrate media and talent access, Dragonfly was launched as a media production company, complete with a state-of-the-art studio, for use by clients and partners for attention and awareness. Dragonfly is the media machine behind the 7-time Telly Award winning video docuseries, “TrueFuture,” of which Joe is the host. He is also the founder of TMGPulse, a MedTech news and opinion website.

Joe is an active member of the medtech and investor community. He sits on industry boards and serves as an adviser to many emerging tech startups and technology accelerators as well as being an angel investor. He holds an engineering degree from The University of Dayton, Ohio.

Sandra obtained her Ph.D. degree in Chemistry from Tufts University and a M.S. in Chemistry from Michigan State University.

Amrish received his degrees in Electrical and Electronic Engineering at the Nanyang Technological University. His graduate studies research led to co -founding Biorithm, a medtech company developing solutions to improve access to care in pregnancy. Amrish has led development of Femom, Biorithm’s flagship product, and driving research globally. Leading Biorithm into the next phase of commercialisation and development, Amrish is part of a diverse team hoping to make a change in womens’ lives.

Dr. Nathan Netravali currently heads Smith + Nephew’s AI Center of Excellence for R&D as well as their Advanced Modeling Development teams.  He is responsible for driving innovation and research to enable Smith + Nephew’s product portfolio for orthopedics, sports medicine, and wound care through the integration of AI and computational simulation.  He has over 10 years of experience working in medical devices with a specific focus on incorporating robotics and technology to enhance patients’ lives.

Nathan received his BS in Biological and Environmental Engineering from Cornell University and his MS and PhD in Mechanical Engineering from Stanford University.  He has published 10 manuscripts, 3 book chapters, and roughly 30 conference presentations along with over 10 patents granted to date.  In his spare time, Nate likes to cook, play soccer, and spend time with his wife and 2 kids.

Stacey is a leader in medical technology with 20 years of experience in medical device research, development and commercialization. Prior to joining Endogenex, she was the Chief Commercial Officer at Butterfly Network, leading planning, organization, sales and marketing. She has also held positions as President of Medtronic’s Neurovascular Operating Unit and as Vice President of Global Medical Affairs and Clinical Affairs at Covidien’s Neurovascular Division. Stacey spent her early career in a variety of clinical development roles at Kinetic Concepts and began her career in critical care and trauma nursing, nursing education, and directed the human subject research program for Texas Tech University Health Sciences Centers.

Arvind Ramadorai is Head of Innovation for the Medtronic Surgical Robotics business. He has experience in driving surgical innovation leveraging robotics and digital technologies. His prior experience includes management consulting experience with PRTM, a global management consulting firm and driving intrapreneurial activities in companies like Honeywell, iRobot as well as stints at VC-funded start-up companies.  Arvind has a PhD in Robotics from Washington University and MBA from London Business School.

A high-energy, connection-driven, non-profit executive, with a background in life sciences, technology and robotics engineering, Rachel joined MassMEDIC as Vice President in February 2020. During her tenure, the organization has tripled its headcount and increased its operating budget by more than 40%. Rachel joined the organization just weeks before the COVID-19 pandemic shut down all in-person events, and pivoted its in-person events strategy, launching a virtual events campaign to serve members and keep the medtech community connected.   

Promoted to Chief Operating Officer of MassMEDIC in 2021, Rachel is responsible for executing the organization’s strategy, including cultivating community partnerships and employee development.  She guides the direction and execution of the organizations programming and community collaborations, including Think Tanks on patient engagement, Working Groups around digital health, and she leads the MassMEDIC’s IGNITE Accelerator Program.    

As President of MassMEDIC IGNITE, one of medtech’s most successful accelerators, it has been her honor to help women- and minority-led ventures, raise more than $100M in the past two years. Their goal, and hers, is to drastically improve how medicine is practiced and challenge the standard of care.  

Rachel has spent the last 15 years in life sciences, primarily focusing on promotion of this important industry through business development and marketing. Through roles at Delve, Acorn Product Development and MPR, her skills have been centered on developing new strategic relationships, growing teams, and initiating thought leadership initiatives to drive awareness.  

​

​

Alicia Chong Rodriguez is the Founder and CEO at Bloomer Tech, a company addressing sex-differences in cardiovascular care for women by using Tech-Augmented Garments (TAG) for personalized healthcare. She graduated in Electrical Engineering & Computer Science from MIT along with the MIT Integrated Design and Management Program. Her research focused on sex-specific, computationally-generated, cardiac biomarkers at the MIT Computational Cardiovascular Research Group. She received the MIT Legatum Fellowship and the Biennial MIT Graduate Women of Excellence Award. Her TED Talk on A SMART BRA FOR BETTER HEART HEALTH has over 1.9 million views. In 2023, Bloomer Tech was awarded as a Tech Pioneer by the World Economic Forum. She has also been recognized as a TED Fellow, Medtech Boston 40 under 40 Healthcare Innovator, and in the top 100 Female Founders across the U.S. by Inc Magazine.

Kate Rumrill is President and CEO of Ablative Solutions, a clinical stage company developing the Peregrine System, an alcohol mediated renal denervation product, for the treatment of hypertension. A seasoned professional. with over 30 years of pharmaceutical and medical device experience, Kate brings a wealth of knowledge and insights to the MassMedic Board.  She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. Most recently, Kate was the President and CEO of NeoSync, Inc., a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with Covidien’s Peripheral Vascular Division. She has extensive experience in product development and new product launches, most notably through her time at Covidien and Eli Lilly & Company.

Deepak brings over 13 years of healthcare and consulting experience to Trinity, with a strong presence in both the United States and Europe. His expertise encompasses a diverse spectrum, collaborating with prominent global MedTech, digital health, diagnostics, private equity, and contract development and manufacturing organizations. His contributions have extended across critical domains such as commercial strategy, business strategies, go-to-market planning, due diligence, health economics and outcomes research (HEOR), and reimbursement strategies. Moreover, Deepak is deeply involved in facilitating collaboration between healthcare providers and the MedTech industry, bridging the gap between innovation and accessibility.

 Prior to joining our team at Trinity, Deepak held the position of Managing Partner at Alira Health, where he played a pivotal role in fostering the growth of MedTech practice since 2013. His leadership extended across continents, including the United States, Europe, and India. Notably, Deepak has made significant strides in various therapeutic areas and maintains a keen interest in the convergence of pharmaceuticals and MedTech, recognizing the evolving landscape of healthcare.

 Deepak’s academic achievements include a Master of Public Health (MPH) from Harvard T.H. Chan School of Public Health, an MBA from Reutlingen University in Germany, and a bachelor’s degree in computer science from National Institute of Technology in India.

Holly is Vice President and a Senior Partner at The Mullings Group, and has been a part of the firm for 25+ years. She believes the most productive and fulfilling organizations are built on the complementary forces that make up a team. Her bidirectional approach to each search allows her to put the best interest of both the individual and the company at the center of her team’s work. She is passionate about the medical device industry, which works to elevate health and healthcare, the individual careers we help build, and the team at TMG. These individuals keep Holly committed to being better every day.

Continuously giving back to the industry, Holly is a member, guest speaker, and advocate for MassMEDIC’s Women in Medtech organization. She also hosts two podcasts, The Power Curve, and Tech Talks with Holly Scott.

Holly is a graduate of the University of Florida with a psychology major and a business minor. She has also been awarded Certified Senior Account Manager (CSAM) by MRINetwork, an international network of recruiting firms.

Martha Shadan was the president and chief executive officer at Miach Orthopaedics from 2019 to 2022. During her tenure, she led the company through the FDA approval process and received the first DeNovo in Sports Medicine. During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.

Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations. Prior to joining Rotation Medical, she was the president of the Trauma Division at Zimmer where she managed the P&L for the global business. Shadan served at Covidien as vice president/general manager of Vascular Therapies and vice president/general manager BioSurgery and Sports Surgery. Other companies that have benefited from Shadan’s experience and leadership include Bristol Myers Squibb Co. and Merck Millipore.

Shadan is actively involved with the Advanced Medical Technology Association (AdvaMed). She has been on the Board of Directors since 2017 and is a current member and past chair of the Accel Board of Directors. Shadan is the past chair of the Diversity and Inclusion Committee for AdvaMed and is a founding member of the Leadership Circle for the Women’s Executive Network (WEN).  Shadan serves on the board of CVRx, LeMaitre and is the chair of the board of Brilliant Strings Therapeutics.   She is also a board advisor for several other companies.

Shadan holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.

Dr. Sigman is a national and internationally recognized leader in Opioid Sparing Surgery.  He is an Orthopedic Surgeon that specializes in the knee and shoulder.  He has been in clinical practice for over 25 years and is a leader in professional education, medical device development, and has numerous peer reviewed publications. He is the team physician at UMASS Lowell. He is a member of Governor Bakers Commission to establish a pain management access program in the Commonwealth of Massachusetts.

He did his sports medicine fellowship at the prestigious Kerlan Jobe Clinic in Los Angeles. His Opioid Sparing leadership propelled him to become a Fellow of the Worlds Society on Sports and Exercise Medicine, and most recently has had the honor of becoming a Fellow of the Royal College of Surgeons in Ireland.

In addition, to his clinical responsibilities Dr. Sigman is the Chief Medical Officer for OrthoLazer Orthopedic Laser Centers. The OrthoLazer franchise was developed to provide an alternative treatment option for acute and chronic pain to help combat the Opioid crisis.  Dr. Sigman is an accomplished national speaker and has a TED talk about his Journey of Opioid Sparing Surgery. Dr. Sigman is also the host of the popular The Ortho Show podcast. He is a TEDx talk speaker.

Upma Sharma has dedicated her career to transforming medicine with materials. Under her leadership, Arsenal Medical has established its platform of purpose-built biomaterials, achieved FDA breakthrough device status and IDE approval for ResQFoam™, and secured over $65M of non-dilutive funding from a diverse group of partners, including the Department of Defense, DARPA, NIH (both National Cancer Institute and National Heart, Lung, and Blood Institute), and Massachusetts Life Sciences Center. 

Upma joined the company as a research scientist, and her role quickly expanded. She led Arsenal’s ResQFoam foundational program from concept to the clinic, guiding product development, GMP contract manufacturing, the regulatory process through IDE approval, and clinical trial design. Today, Upma leads the expansion of Arsenal’s biomaterial platform for strategic growth across high-value clinical indications. 

Prior to joining Arsenal, Upma was a key member of the Lyra Therapeutics team that created a novel bioresorbable scaffold. She oversaw the development of this technology for the treatment of chronic sinusitis, including leading a Phase I clinical study. The data from that study led to subsequent venture funding and the eventual IPO of Lyra Therapeutics. 

Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, she was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents. 

Dr. Joe Shonkwiler joined the Advanced Research Projects Agency for Health (ARPA-H) as the agency’s inaugural Chief Operating Officer in 2023.  ARPA-H is a newly formed federal agency with over $2.5 billion in funding to make pivotal investments in break-through technologies and broadly applicable platforms, capabilities, and resources that have the potential to transform important areas of medicine and health.  ARPA-H focuses on “moonshot” investments in solutions that cannot readily be accomplished through traditional research or commercial activity.  As COO, he leads all the business and administrative operations for the agency, including technology transfer, finance, IT and data infrastructure, contracting and acquisitions, and human resources.

Dr. Shonkwiler joined ARPA-H from the healthcare and life sciences startup business development team at Amazon Web Services (AWS).  In that role, he and his team were responsible for putting Amazon’s people, technology, best practices, and relationships to work alongside investors and their portfolio companies to accelerate scientific, engineering, and commercial efforts in biotech, health tech, and med tech.  He not only worked directly with hundreds of healthcare and life science startups from conception to exit, but also founded and hosted the AWS Health Innovation Podcast, a weekly podcast featuring entrepreneurs and investors driving progress in healthcare and life science from across the globe.

Prior to joining Amazon, Dr. Shonkwiler was the Vice President of Adoption and Training at Aledade, a venture-backed startup helping independent primary care practices succeed in value-based care.  In that role, he led national implementation of Aledade’s software and services as well as all internal and external training on principles of population health management and value-based care.  Before Aledade, he was the CEO of CollectedMed, a cloud-based health education software startup spun out of Columbia University’s Department of Surgery.

Dr. Shonkwiler also spent time on Capitol Hill as the Healthcare Legislative Assistant for former United States Senator Rob Portman, serving as the Senator’s senior health policy advisor for all matters related to federal health policy.  He began his career as a general surgery resident at Columbia University Medical Center/New York Presbyterian Hospital.

He has a BA from the University of Notre Dame, an MPP from Princeton University, an MBA from MIT, and an MD from Columbia University.

Kevin P. Smith is the General Counsel and EVP for Business Development at Sirtex Medical.  In this role, Kevin focuses on growing the product portfolio of the company in the interventional radiology and oncology markets, as well as managing the risks to the business.

Before joining Sirtex in 2018, Kevin served as VP and Associate General Counsel at Flexion Therapeutics, managing intellectual property and corporate governance. Prior to that, he was General Counsel for the Danaher Life Sciences Platform, leading the legal, compliance, and intellectual property functions for the operating companies within the platform. Kevin has also held senior legal leadership positions within Novartis Pharmaceuticals in Switzerland and Massachusetts, including as General Counsel for the Novartis Molecular Diagnostics Unit, focused on developing tools to further personalized medicine solutions. Before moving in-house, Kevin worked for multinational law firms in New York, Silicon Valley, and London.

A member of the California, Massachusetts, and New York State bars, Kevin is also a registered patent attorney with the U.S. Patent and Trademark Office.  He also serves as a Director for the non-profit, National Immigration Litigation Alliance, as well as being a Director for BlackSwan Vascular, Inc. and Nanospectra Biosciences, Inc.

With a foundation in systems thinking, product development, operations, and clinical informatics, Carole is the principal consultant and CEO of Three Mountains Consulting where she develops and deploys strategies to increase clinical engagement, highlighting critical market trends/insights, ensuring business growth in-line with market trends. Leveraging her industry expertise in data system design and strategy, she ensures companies achieve engagement, traction, credibility and market share.

Carole has led the development of ground-breaking clinical decision support products, that direct personalized clinical decision strategies, in effect managing patient populations. Carole believes it is critical to bring actionable data insights to clinicians so that decision making is representative of the best possible clinical outcome, surfacing personalized treatment decision patterns which drive health economic outcome research. Her adept ability to engage clinicians and healthcare organizations, permits Carole to find the balance between what is and what needs to be for sustainable business growth and competitive edge.

Mr. Usen has extensive commercial and operational experience with a proven track record of leading large, complex global businesses across several highly regarded medical device companies. Todd joined Minerva Surgical, a publicly traded women’s health organization, as President & CEO on January 3, 2023. He has led a complete restructuring of the organization.  Prior, he spent four years as the Chief Executive Officer of Activ Surgical, a digital surgery company focused on advanced surgical imaging and AI, where he oversaw the FDA/CE clearance of its ActivSight technology, as well as leading four fundraising rounds totaling over $92 million. From 2015 to 2019, Mr. Usen was President, Medical Systems Group, for Olympus Corporation of the Americas, where he took charge of a complex $2B+ business and restructured the company for leaner growth and investment, drove successful mergers and acquisitions activity, led the expansion from 6 medical divisions to 11 in 3.5 years. Prior to that, Mr. Usen served in executive positions including President, United States Orthopedics, Senior Vice President & General Manager, Joint Reconstruction, and Senior Vice President Sports Medicine at Smith and Nephew, and Vice President Sales and Director of Sales at Boston Scientific Corporation. Mr. Usen holds a BS in Marketing from the Isenberg School at the University of Massachusetts and did his MBA work at Pepperdine University.

Todd is married to Melissa, and they have three children, Morgan, Rachel and Tyler.

As President and Chief Executive Officer of Morphic Medical®, Joseph Virgilio brings over 20 years of diverse experience and knowledge to the organization from positions held in the medical device industry in the areas of sales, marketing, operations, and general management. Joe’s track record of aggressive revenue growth results from his ability to develop and execute successful strategic sales and marketing plans in addition to recruiting, training, and motivating highly effective and specialized cross-functional teams. Adept at leading organizational turn-around and integration activities, Joe also has expertise in organizational development and restructuring, corporate partnerships, and distribution strategies.

Prior to joining Morphic Medical in 2020, Joe served as President and General Manager for Amann Girrbach, a global leader in digital dental technology. He has also held the position of Vice President of Sales, The Americas at Surgical Specialties Corporation, as well as Vice President of Sales and Global Marketing at Aptus Endosystems (acquired by Medtronic). Joe spent the early part of his medical device career at Boston Scientific followed by almost a decade at Medtronic in roles of increasing responsibility.

Joe is a graduate of Colgate University and has completed executive education courses at the University of Pennsylvania, Wharton School of Business, the University of North Carolina, Chapel Hill, Kenan-Flagler School of Business, and Columbia University Business School.

Jeff Valk is co-founder and CEO of Admetsys. Prior to taking the helm of Admetsys, he was the company’s Chief Technologist, responsible for development of its automated glucose control and continuous diagnostics system for hospital care and the state-of-the-art informatics and network monitoring technologies that support it. Jeff is a hardware and software engineer by background, specializing in the design of adaptive systems and has technical expertise in areas including machine intelligence, robotics, distributed systems, and human-computer interaction.

Chris is a Principal with Clarivate (formerly DRG) Consulting.   He has been part of the team for more than 8 years and has been involved in 75+ projects supporting clients with new product planning.  Prior to entering consulting, he received a PhD in Microbiology from Harvard University and a BS in Biochemistry from Brown University.

Jason Winder is the CEO of Sonogen Medical, a Baltimore based startup and certified Maryland biotechnology company through the state’s BIITC program. Sonogen is working to commercialize an ultrasonic bone growth stimulation device that’s been proven to dramatically speeds bone fracture healing time while providing real-time feedback on both patient compliance and the fracture healing process. Prior to Sonogen, Jason was the founder and CTO of Aerstone, a boutique cybersecurity consultancy that’s just one of five firms in the world certified by the NSA for vulnerability assessment work. Jason is a seasoned entrepreneur and risk management specialist, having provided extensive technical support over the course of several decades to the US military, intelligence community, and private industry. He is bilingual English/French, holds both an MBA and a Master of International Business from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh, as well as a Bachelor of Arts in Economics from Drew University. In his spare time Jason enjoys blues guitar, writing, cooking, and golf — at varying levels of proficiency.

Adrienne Zepeda is the Group Event Director at Informa Markets where she is responsible for MD&M West, BIOMEDevice Boston and BIOMEDevice Silicon Valley.